CLINICAL_TRIALS
trial_result
· 2019-06-18
Clinical Trial Update: A Study of Subcutaneous Abatacept to Treat Diffuse Cutaneous Systemic Sclerosis [Phase 2]
Summary
Phase 2 clinical trial evaluating subcutaneous abatacept for diffuse cutaneous systemic sclerosis has completed with results posted in 2019.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Dinesh Khanna, MD, MS | Conditions: Diffuse Cutaneous Systemic Sclerosis | Phase 2 | Status: COMPLETED | Results posted: 2019-06-18